Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0V7FG
|
||||
| Former ID |
DIB013017
|
||||
| Drug Name |
SPH-1285
|
||||
| Synonyms |
Galantamine derivatives, Sanochemia; SPH-1285; SPH-1286; SPH-1359
|
||||
| Indication | Alzheimer disease [ICD9: 331; ICD10:G30] | Preclinical | [1] | ||
| Company |
Sanochemia Pharmazeutika AG
|
||||
| Structure |
|
Download2D MOL |
|||
| Canonical SMILES |
[C@@]123c4c(O[C@@H]1C[C@H](C=C2)O)c(ccc4CN(CC3)CCCN1CCC<br />CC1)OC.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O
|
||||
| CAS Number |
CAS 273930-29-3
|
||||
| Target and Pathway | |||||
| Target(s) | Acetylcholinesterase | Target Info | Inhibitor | [2] | |
| KEGG Pathway | Glycerophospholipid metabolism | ||||
| Cholinergic synapse | |||||
| PANTHER Pathway | Muscarinic acetylcholine receptor 1 and 3 signaling pathway | ||||
| Muscarinic acetylcholine receptor 2 and 4 signaling pathway | |||||
| Nicotinic acetylcholine receptor signaling pathway | |||||
| Pathway Interaction Database | ATF-2 transcription factor network | ||||
| PathWhiz Pathway | Phospholipid Biosynthesis | ||||
| WikiPathways | Monoamine Transport | ||||
| Biogenic Amine Synthesis | |||||
| Acetylcholine Synthesis | |||||
| Integrated Pancreatic Cancer Pathway | |||||
| References | |||||
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015422) | ||||
| REF 2 | Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: effects on the course of Alzheimer's disease. Biol Psychiatry. 2001 Feb 1;49(3):289-99. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.